(Colorectal Cancer) Is Adagrasib ± Cetuximab Effective? KRYSTAL-1 Phase 1/2 Trial Results
Medical Supporter — Мэдээллийн мэдэгдэл
Энэ нийтлэл нь олон улсын эмнэлгийн мэдээллийн эмхэтгэл бөгөөд эмнэлгийн зөвлөгөө биш; таны эмчийн оношлогоо, эмчилгээний төлөвлөгөөг орлохгүй. Энд буй мэдээлэл нь Японы томоохон эмнэлгийн байгууллагуудын нээлттэй эх сурвалжаас эмхэтгэсэн бөгөөд аливаа эмчилгээний тохиромж, үр дүн өвчтөн бүрээр өөр тул мэргэшсэн эмч тус бүрчлэн үнэлэх ёстой.
- February 1, 2023
- 1 min read
On December 21, 2022, Rona Yaeger and colleagues from Memorial Sloan Kettering Cancer Center published results in the New England Journal of Medicine from the KRYSTAL-1 Phase 1/2 clinical trial evaluating the efficacy and safety of adagrasib ± cetuximab in previously treated KRAS G12C mutation-positive metastatic colorectal cancer patients.
Trial Design:
The KRYSTAL-1 trial was an open-label, non-randomized study enrolling previously treated KRAS G12C mutation-positive metastatic colorectal cancer patients (N=76), divided into:
- Adagrasib monotherapy group: 600 mg twice daily (N=44)
- Adagrasib 600 mg twice daily + cetuximab 250 mg/m² weekly or 500 mg/m² biweekly (N=32)
Primary endpoints were objective response rate (ORR) and safety.
Results at median follow-up of 20.1 months (monotherapy) and 17.5 months (combination):
| Endpoint | Adagrasib alone | Adagrasib + Cetuximab |
|---|---|---|
| ORR | 19% | 46% |
| Median duration of response | 4.3 months | 7.6 months |
| Median PFS | 5.6 months | 6.9 months |
Safety:
Grade 3–4 adverse events: Adagrasib alone 34% vs. adagrasib + cetuximab 16%.
Conclusion: Based on the KRYSTAL-1 trial results, Rona Yaeger and colleagues concluded that adagrasib ± cetuximab demonstrated favorable anti-tumor activity in previously treated KRAS G12C-mutant metastatic colorectal cancer patients, with the combination showing a duration of response exceeding 6 months.
Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2212419
Colorectal Cancer | KRAS G12C | Adagrasib | Cetuximab
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Японд эмчлүүлэхээр төлөвлөж байна уу? Мэдээлэл, тусламж хэрэгтэй юу?
Бид Японд эмчлүүлэхэд шаардлагатай мэдээллийг эмхэтгэх, Японы эмнэлгийн байгууллагуудтай холбогдох, хоёр дахь саналын зөвлөгөө зохион байгуулахад тусална.Анхны зөвлөгөө үнэгүй; зөвлөх таны дараагийн алхмыг тодорхой болгоход тусална.
Figure 1
Figure 2
Figure 3
Figure 4